23 research outputs found
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.
The European Neuroendocrine Tumor Society (ENETS) proposed standard of care guidelines for pathology in 2009. Since then, profound changes in the classification have been made, dividing neuroendocrine neoplasia (NEN) into well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC) in the 2010 WHO classification. The 7th edition of the TNM classification (2009) included NEN for the first time, widely adapting ENETS proposals but with some differences for NEC and for NET of the pancreas and the appendix. Therapy guidelines for gastroenteropancreatic NET were updated in 2016. The need for an update of the standards of care prompted the ENETS to organize a consensus conference which was held in Antibes in 2015; a working group was designated to propose pathological standards of car
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Unmet medical needs are not infrequent in oncology, and these needs are
usually of higher magnitude in rare cancers. The field of neuroendocrine
neoplasms (NENs) has evolved rapidly during the last decade, and,
currently, a new WHO classification is being implemented and several
treatment options are available in the metastatic setting after the
results of prospective phase III clinical trials. However, several
questions are still unanswered, and decisions in our daily clinical
practice should be made with limited evidence. In the 2016 meeting of
the advisory board of the European Neuroendocrine Tumor Society (ENETS),
the main unmet medical needs in the metastatic NENs setting were deeply
discussed, and several proposals to try to solve them are presented in
this article, including biomarkers, imaging, and therapy
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan). (C) 2017 S. Karger AG, Base